Why the study?
Despite the increasing prevalence of PH-LHD, clinicians face a paucity of knowledge regarding its hemodynamic definition, diagnosis, treatment modalities, and prognosis, alongside mixed clinical trial results on pulmonary vasodilator therapies.
Answers are grounded in this paper and cite their sources.
This expert review outlines the critical role of meticulous hemodynamic evaluation and summarizes current therapeutic strategies for managing pulmonary hypertension associated with left heart disease.
Pulmonary hypertension associated with left heart disease (PH-LHD) remains the most common cause of pulmonary hypertension globally. Etiologies include heart failure with reduced and preserved ejection fraction and left-sided valvular heart diseases. Despite the increasing prevalence of PH-LHD, there remains a paucity of knowledge about the hemodynamic definition, diagnosis, treatment modalities, and prognosis among clinicians. Moreover, clinical trials have produced mixed results on the usefulness of pulmonary vasodilator therapies for PH-LHD. In this expert review, we have outlined the critical role of meticulous hemodynamic evaluation and provocative testing for cases of diagnostic uncertainty. Therapeutic strategies-pharmacologic, device-based, and surgical therapies used for managing PH-LHD-are also outlined. PH-LHD in advanced heart failure, and the role of mechanical circulatory support in PH-LHD is briefly explored. An in-depth understanding of PH-LHD by all clinicians is needed for improved recognition and outcomes among patients with PH-LHD.
No takes yet. Share an insight, caveat, or question.
Ilonze et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: